Atea Pharmaceuticals, Inc.
AVIR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $282 | $254 | $400 | $740 |
| - Cash | $65 | $144 | $188 | $764 |
| + Debt | $2 | $2 | $3 | $0 |
| Enterprise Value | $219 | $113 | $215 | -$24 |
| Revenue | $0 | $0 | $0 | $351 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$83 | -$70 | -$62 | $184 |
| % Margin | – | – | – | 52.4% |
| EBITDA | -$132 | -$120 | -$111 | $138 |
| % Margin | – | – | – | 39.4% |
| Net Income | -$168 | -$136 | -$116 | $121 |
| % Margin | – | – | – | 34.5% |
| EPS Diluted | -2 | -1.63 | -1.39 | 1.37 |
| % Growth | -22.7% | -17.3% | -201.5% | – |
| Operating Cash Flow | -$135 | -$85 | -$121 | -$87 |
| Capital Expenditures | $0 | $0 | -$2 | -$0 |
| Free Cash Flow | -$135 | -$85 | -$123 | -$87 |